These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16104618)

  • 41. Cardiac Medication Use in Patients with Acute Myocardial Infarction and Nonobstructive Coronary Artery Disease.
    Adatia F; Galway S; Grubisic M; Lee M; Daniele P; Humphries KH; Sedlak TL
    J Womens Health (Larchmt); 2017 Nov; 26(11):1185-1192. PubMed ID: 28384014
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Changes in the prescription of cardiovascular prevention drugs in France between 1995 and 2003: factors influencing the gap between evidence base medicine and clinical practice].
    Philippe F; Cambou JP; Danchin N; Thomas D
    Ann Cardiol Angeiol (Paris); 2005 Dec; 54 Suppl 1():S30-6. PubMed ID: 16411649
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Difference in Medication Adherence Between Patients Prescribed a 30-Day Versus 90-Day Supply After Acute Myocardial Infarction.
    Rymer JA; Fonseca E; Bhandary DD; Kumar D; Khan ND; Wang TY
    J Am Heart Assoc; 2021 Jan; 10(1):e016215. PubMed ID: 33342227
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Beta-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada.
    Johnson D; Jin Y; Quan H; Cujec B
    J Am Coll Cardiol; 2003 Oct; 42(8):1438-45. PubMed ID: 14563589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sex Differences in Cardiac Medication Use Post-Catheterization in Patients Undergoing Coronary Angiography for Stable Angina with Nonobstructive Coronary Artery Disease.
    Galway S; Adatia F; Grubisic M; Lee M; Daniele P; Humphries KH; Sedlak TL
    J Womens Health (Larchmt); 2017 Sep; 26(9):976-983. PubMed ID: 28384013
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery.
    Goyal A; Alexander JH; Hafley GE; Graham SH; Mehta RH; Mack MJ; Wolf RK; Cohn LH; Kouchoukos NT; Harrington RA; Gennevois D; Gibson CM; Califf RM; Ferguson TB; Peterson ED;
    Ann Thorac Surg; 2007 Mar; 83(3):993-1001. PubMed ID: 17307447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Five-year follow-up of drug utilization for secondary prevention in coronary artery disease.
    Apikoglu Rabus S; Izzettin FV; Sancar M; Karakaya O; Kargin R; Yakut C
    Pharm World Sci; 2008 Dec; 30(6):753-8. PubMed ID: 18563622
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In-hospital prescriptions of secondary-prevention medications for post-acute coronary syndrome patients in South Korea
.
    Kang HB; Choi M; Yoon SG; Cho YS; Je NK
    Int J Clin Pharmacol Ther; 2018 Jan; 56(1):1-11. PubMed ID: 29168689
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secondary prevention for coronary artery disease: are we following the guidelines?
    Syed IA; Riaz A; Ryan A; Reilly MO
    Ir J Med Sci; 2010 Dec; 179(4):535-7. PubMed ID: 20676796
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction.
    Berger AK; Duval S; Krumholz HM
    J Am Coll Cardiol; 2003 Jul; 42(2):201-8. PubMed ID: 12875751
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interhospital Variability in Drug Prescription After Acute Coronary Syndrome: Insights From the ACDC Study.
    Ferreira-González I; Carrillo X; Martín V; de la Torre Hernández JM; Baz JA; Navarro Manchón J; Masotti M; Cequier Á; Cárdenas M; Alfonso Manterola F;
    Rev Esp Cardiol (Engl Ed); 2016 Feb; 69(2):117-24. PubMed ID: 26253861
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Evaluation of management of infarction in the Franche Comté province by the use of the Franche Comté Cardiology Registry, May 2005-May 2006].
    Schiele F; Fouché R; Lassabe G; Bohigas P; Magnin D; Bechetoille P; Thebault L; Faivre R; Boumal D; Frison J; Bassand JP;
    Arch Mal Coeur Vaiss; 2007 Nov; 100(11):917-24. PubMed ID: 18209692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secondary prevention in coronary heart disease: goal achievement and drug prescribing.
    Giverhaug T; Bruland C; Trovik T
    Pharm World Sci; 2005 Dec; 27(6):472-4. PubMed ID: 16341957
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of preventive cardiovascular pharmacotherapy after coronary artery bypass graft surgery.
    Barry AR; Koshman SL; Norris CM; Ross DB; Pearson GJ
    Pharmacotherapy; 2014 May; 34(5):464-72. PubMed ID: 24877186
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drug secondary prevention in postmenopausal women with ischemic heart disease.
    Zdrenghea D; Pop D; Sitar-Tăut A; Cebanu M; Zdrenghea V
    Rom J Intern Med; 2009; 47(1):41-5. PubMed ID: 19886068
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Trends in the use of pharmacotherapies for acute myocardial infarction among physicians who design and/or implement randomized trials versus physicians in routine clinical practice: the MILIS-TIMI experience. Multicenter Investigation on Limitation of Infarct Size. Thrombolysis in Myocardial Infarction.
    Kizer JR; Cannon CP; McCabe CH; Mueller HS; Schweiger MJ; Davis VG; Perritt R; Antman EM
    Am Heart J; 1999 Jan; 137(1):79-92. PubMed ID: 9878939
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Revascularization and cardioprotective drug treatment in myocardial infarction patients: how do they impact on patients' survival when delivered as usual care.
    Vanasse A; Courteau J; Niyonsenga T
    BMC Cardiovasc Disord; 2006 May; 6():21. PubMed ID: 16674817
    [TBL] [Abstract][Full Text] [Related]  

  • 58. How Admission to a Vascular Surgery Department Improves Medical Treatment in Patients with Lower Extremity Peripheral Arterial Disease.
    Thiney M; Della Schiava N; Feugier P; Lermusiaux P; Ninet J; Millon A; Long A
    Ann Vasc Surg; 2017 Apr; 40():85-93. PubMed ID: 27908822
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Impact of different intervention models on adherence to secondary prevention therapies in patients with acute coronary syndrome].
    Liu J; Wang W; Liu J; Wang Y; Qi Y; Sun JY; Zhao D
    Zhonghua Xin Xue Guan Bing Za Zhi; 2018 Feb; 46(2):124-130. PubMed ID: 29495236
    [No Abstract]   [Full Text] [Related]  

  • 60. Adherence to agents acting on the renin-angiotensin system in secondary prevention of non-fatal myocardial infarction: a self-controlled case-series study.
    Ortolani P; Di Bartolomeo S; Marino M; Vagnarelli F; Guastaroba P; Rapezzi C; De Palma R
    Eur Heart J Cardiovasc Pharmacother; 2015 Oct; 1(4):254-9. PubMed ID: 27532449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.